» Articles » PMID: 20661154

Novel Evidence for Chronic Exposure to Endotoxin in Human Nonalcoholic Steatohepatitis

Overview
Specialty Gastroenterology
Date 2010 Jul 28
PMID 20661154
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endotoxin is hypothesized to play an important role in the activation of inflammatory pathways associated with nonalcoholic steatohepatitis (NASH). However, demonstration of hepatic endotoxin exposure is challenging due to the inaccessibility of the portal circulation. Furthermore, reliable measurement of the relatively low endotoxin levels in plasma of patients with liver disease and subsequent interpretation remain difficult.

Goals: In this study, we used the EndoCab assay that measures endogenous antibodies to the core region of endotoxin to estimate hepatic endotoxin exposure over time.

Study: IgG levels against endotoxin were measured in peripheral plasma obtained from 21 severely obese patients with NASH and 9 severely obese patients with healthy livers.

Results: Plasma IgG levels against endotoxin were significantly elevated in patients with NASH compared with patients with healthy livers (48±63 GMU/mL vs. 10±13 GMU/mL). Moreover, these IgG levels progressively increased with NASH grade (grade 1 29±37; grade 2 58±51; grade 3 84±132 GMU/mL, P<0.05). There was no relation between plasma IgG levels and NASH stage.

Conclusions: Plasma IgG levels against endotoxin were found to be increased in biopsy-proven human NASH and increased with aggravated inflammation in NASH, suggesting a relationship between chronic endotoxin exposure and the severity of human NASH.

Citing Articles

Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.

Rondanelli M, Borromeo S, Cavioni A, Gasparri C, Gattone I, Genovese E Metabolites. 2025; 15(2).

PMID: 39997751 PMC: 11857149. DOI: 10.3390/metabo15020127.


Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease.

Gao Y, Lin J, Ye C, Guo S, Jiang C Liver Res. 2025; 7(3):165-176.

PMID: 39958385 PMC: 11792070. DOI: 10.1016/j.livres.2023.09.002.


Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.

Termite F, Archilei S, DAmbrosio F, Petrucci L, Viceconti N, Iaccarino R Antioxidants (Basel). 2025; 14(1).

PMID: 39857390 PMC: 11759774. DOI: 10.3390/antiox14010056.


Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.

Rochon J, Kalinowski P, Szymanek-Majchrzak K, Grat M World J Gastroenterol. 2024; 30(23):2964-2980.

PMID: 38946874 PMC: 11212696. DOI: 10.3748/wjg.v30.i23.2964.


The Role of the Gastrointestinal Microbiome in Liver Disease.

Shalaby N, Samocha-Bonet D, Kaakoush N, Danta M Pathogens. 2023; 12(9).

PMID: 37764895 PMC: 10536540. DOI: 10.3390/pathogens12091087.